PHRRF — Pharmather Holdings Share News
0.000.00%
Last trade - 00:00Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application
Brief: PharmaTher Announces Update On FDA New Drug Application For Ketamine
Brief: PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001
Brief: Pharmather Announces Assigned FDA Approval Goal Date Of Its Priority Original Abbreviated New Drug Application For Ketamine
Brief: Pharmather Provides Update Of Its Priority Original Abbreviated New Drug Application For Ketamine
Brief: PharmaTher Provides Update Of Its Priority Original Abbreviated New Drug Application For Ketamine
Brief: Pharmather Provides Update For Expected FDA Approval Of Ketamine
Brief: PharmaTher Submits Application for KETARX to FDA
Brief: Pharmather Initiates Filing Of Abbreviated New Drug Application For Ketarx To The FDA
Brief: PharmaTher And Vitruvias Enter Into Collaboration Agreement For Commercialization Of KETARX In The U.S.
Brief: Pharmather Holdings Submits Fast Track Application To FDA For Ketarx For Treatment Of Parkinson's Disease
Brief: Pharmather Holdings Announces Update Of Type C Meeting With The FDA For Ketarx™ (Ketamine) In Parkinson’S Disease
Brief: Pharmather Holdings Bags FDA's Orphan Drug Tag For Drug Treating Rett Syndrome
Brief: Pharmather Holdings Submits FDA Meeting Package To Discuss Phase 3 Program And Fast Track Designation For Ketarx™ (Ketamine) In Parkinson’S Disease
Brief: FDA Grants 'Orphan Drug' Status To PharmaTher's Ketamine For Prevention Of Ischemia-Reperfusion Injury From Organ Transplantation
Brief: Pharmather Granted FDA Orphan Drug Designation For Ketamine To Treat Status Epilepticus